Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients
Metrics: PDF 2622 views | HTML 3768 views | ?
Anastasia S. Nikitina1,2, Elena I. Sharova1, Svetlana A. Danilenko1, Tatiana B. Butusova1, Alexandr O. Vasiliev3, Alexandr V. Govorov3, Elena A. Prilepskaya3, Dmitry Y. Pushkar3, Elena S. Kostryukova1,2
1Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia
2Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia
3Department of Urology, Moscow State Medical Stomatological University, Moscow, Russia
Anastasia S. Nikitina, email: firstname.lastname@example.org
Keywords: prostate cancer, benign prostatic hyperplasia, RNA biomarkers, RNA-Seq, FFPE
Received: November 01, 2016 Accepted: March 15, 2017 Published: March 23, 2017
Due to heterogeneous multifocal nature of prostate cancer (PCa), there is currently a lack of biomarkers that stably distinguish it from benign prostatic hyperplasia (BPH), predict clinical outcome and guide the choice of optimal treatment. In this study RNA-seq analysis was applied to formalin-fixed paraffin-embedded (FFPE) tumor and matched normal tissue samples collected from Russian patients with PCa and BPH. We identified 3384 genes differentially expressed (DE) (FDR < 0.05) between tumor tissue of PCa patients and adjacent normal tissue as well as both tissue types from BPH patients. Overexpression of four of the discovered genes (ANKRD34B, NEK5, KCNG3, and PTPRT) was validated by RT-qPCR. Furthermore, the enrichment analysis of overrepresented microRNA and transcription factor (TF) recognition sites within DE genes revealed common regulatory elements of which 13 microRNAs and 53 TFs were thus linked to PCa for the first time. Moreover, 8 of these TFs (FOXJ2, GATA6, NFE2L1, NFIL3, PRRX2, TEF, EBF2 and ZBTB18) were found to be differentially expressed in this study making them not only candidate biomarkers of prostate cancer but also potential therapeutic targets.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.